摘要
目的比较齐拉西酮与氯氮平对精神分裂症患者生活质量的影响。方法选取84例患者,随机分为齐拉西酮组42例,氯氮平组42例,分别给予齐拉西酮和氯氮平治疗。疗程12周。在治疗前及治疗2、4、6、8、12周末分别采用阳性与阴性症状量表(PANSS)、副反应量表(TESS)进行疗效、不良反应评定。在治疗前及治疗12周末分别采用生活质量综合评定问卷(GQOLI)、健康状况问卷(SF-36)进行生活质量评估,并对影响生活质量的某些因素进行多元逐步回归分析。结果两组治疗前后PANSS评分差异均有显著性(P<0.05或P<0.01),治疗后组间比较差异无显著性(P>0.05)。治疗后齐拉西酮组GQOLI、SF-36评分均明显高于氯氮平组。精神症状、药物、不良反应和病程依次进入分裂症患者生活质量的多元回归方程。结论齐拉西酮与氯氮平对精神分裂症患者疗效相当,但生活质量优于氯氮平。
Objective To compare the quality of life of schizophrenic patients treated with ziprasidone and clozapine, Methods 84 schizophrenic inpatients were randomly divided into ziprasidone group （n=42） and clozapine group （n = 42） for 12 treatment weeks. Positive and negative syndrome scale （PANSS） and treatment emergent symptoms scale （TESS） were used to evaluated the efficacy and the side effects before and after 2,4,6,8,12 treatment weeks. General quality of life inventory （GQOLI） and short form 36 health survey questionaire （SF-36） evaluated after 12 treatment weeks for two groups, Results The scores of PANSS reduced significantly after treatment in two groups. The factor scores and the total scores of GQOLI, SF-36 were significantly higher in ziprasidone group than that in clozapine group. An analysis of multiple stepwise regressions showed that the main factors inflencing the patients＇ llfe quality were psychotic symptoms, drug, side effect and the duration of disease inturn. Conclusion Ziprasidone and clozapine have similar efficacy in the treatment of schizophrenia, but the patients treated with ziprasidone may have better life quality.
出处
《中国健康心理学杂志》
2008年第8期910-912,共3页
China Journal of Health Psychology
